Scarica l'app Stockscreener
200.05
0.05%
0.09
Dopo l'orario di chiusura:
199.21
-0.84
-0.42%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BIIB Giù?
Forum
Previsione
Frazionamento azionario
Biogen Inc Borsa (BIIB) Ultime notizie
ICICI Prudential Asset Management Co Ltd Has $1.67 Million Stock Holdings in Biogen Inc. $BIIB - MarketBeat
FMR LLC's Strategic Acquisition of Biogen Inc Shares - GuruFocus
Muscle-Relaxing Athletic Shots - Trend Hunter
Biogen Inc. (BIIB) Announces Results of 2026 Annual Meeting of S - GuruFocus
Biogen (NASDAQ: BIIB) director granted 1,505-share equity compensation award - Stock Titan
Biogen (BIIB) director receives 1,505 restricted stock units in grant - Stock Titan
Biogen (NASDAQ: BIIB) grants director 1,505 RSUs vesting by 2026 - Stock Titan
Biogen (NASDAQ: BIIB) director Jesus B. Mantas awarded 1,505-share stock grant - Stock Titan
[Form 4] BIOGEN INC. Insider Trading Activity - Stock Titan
Biogen (NASDAQ: BIIB) awards 1,505 RSUs to company director - Stock Titan
Biogen (BIIB) director Menelas Pangalos receives stock grant and exercises 2,370 RSUs - Stock Titan
Biogen (BIIB) director Lloyd Minor receives 1,505-share equity award in Form 4 filing - Stock Titan
Biogen (NASDAQ: BIIB) director receives 2,005 restricted stock unit award - Stock Titan
Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Biogen Inc. (BIIB) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
City Therapeutics - The Pharma Letter
BIIB Investors Have Opportunity to Join Biogen Inc. Fraud Investigation with the Schall Law Firm - PR Newswire
Did FDA Breakthrough Status for Salanersen Just Shift Biogen's (BIIB) Long-Term SMA Strategy? - simplywall.st
What Makes Denali Therapeutics (DNLI) One of the Best AI Driven Biotech Names - Insider Monkey
Biogen Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Biogen (NASDAQ: BIIB) posts 2026 director and proposal vote tallies - Stock Titan
Biogen (NASDAQ: BIIB) deems Apellis acquisition not significant - Stock Titan
Biogen Inc. stock (US09062X1037): Alzheimer’s setback, pipeline hopes and what’s next - AD HOC NEWS
Biogen (NASDAQ:BIIB) Stock Acquired Rep. Maria Elvira Salazar - MarketBeat
Biogen (NASDAQ:BIIB) Shares Bought Rep. Maria Elvira Salazar - MarketBeat
How Is Biogen’s Stock Performance Compared to Other Biotech Stocks? - Yahoo Finance
Biogen Stock (BIIB) Opinions on Congressional Purchases and Analyst Upgrade - Moomoo
Maria Elvira Salazar invests in Biogen, Datadog and IBM; sells Sherwin-Williams and Whirlpool stocks By Investing.com - Investing.com Nigeria
Is Biogen Inc (BIIB) Overvalued After 3.4% Rally? GF Value Says - GuruFocus
This House of Representative Just Bought Up To $375K In Biogen Stock - Benzinga
Biogen Inc Annual Shareholders Meeting Transcript - GuruFocus
Alzheimer's Therapeutics Market Dominated by North America, Biogen and Eli Lilly Drive Treatment Advances - openPR.com
BIIB Investors Have Opportunity to Join Biogen Inc. Fraud Invest - GuruFocus
Biogen To End Investors' Alzheimer's Drug Case For $18.9M - Law360
Biogen Inc. stock underperforms Monday when compared to competitors - MarketWatch
Biogen Inc. (BIIB) Faces Securities Fraud Investigation After Cl - GuruFocus
Biogen (BIIB) Upgraded to Buy with Target Price of $255 - GuruFocus
Biogen's Base Is Declining — But 8 Pipeline Readouts Could Flip The Story - Benzinga
Biogen to pay $18.9 million to settle investors' claims over Alzheimer's drug - Reuters
2026-06-08 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Biogen Inc. (BIIB) and Encourages Stockholders to Learn More About the Investigation | NDAQ:BIIB | Press Release - Stockhouse
Biogen Inc. stock (US09062X1037): Alzheimer’s portfolio and pipeline in focus after recent updates - AD HOC NEWS
This Biogen Analyst Turns Bullish; Here Are Top 3 Upgrades For Monday - Benzinga
New Progress Toward Public Reimbursement of SKYCLARYS™ for People Living with Friedreich Ataxia in Quebec - BioSpace
Needham upgrades Biogen stock rating on pipeline outlook By Investing.com - Investing.com South Africa
Needham Upgrades Biogen(BIIB.US) to Buy Rating, Announces Target Price $255 - Moomoo
Needham upgrades Biogen stock rating on pipeline outlook - Investing.com
Biogen (BIIB) Upgraded to Buy with Promising Growth Prospects - GuruFocus
BIIB Upgraded by Needham -- Rating Changed to Buy with Price Tar - GuruFocus
Needham Upgrades Biogen to Buy From Hold, Price Target Is $255 - Moomoo
WINTON GROUP Ltd Buys New Stake in Biogen Inc. $BIIB - MarketBeat
Assessing Biogen (BIIB) Valuation After Breakthrough Therapy Status And Positive Lupus Trial Data - simplywall.st
Los Angeles Capital Management LLC Increases Stock Holdings in Biogen Inc. $BIIB - MarketBeat
Biogen Inc. (BIIB) Stock Analysis: Exploring a 12.34% Potential Upside Amid Strategic Collaborations - DirectorsTalk Interviews
TD Asset Management Inc Sells 25,843 Shares of Biogen Inc. $BIIB - MarketBeat
Contrarius Group Holdings Ltd Acquires Shares of 64,952 Biogen Inc. $BIIB - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Biogen Inc. (BIIB) Investors to Inquire about Securities Investigation - The National Law Review
CIBC Asset Management Inc Trims Stock Position in Biogen Inc. $BIIB - MarketBeat
Biogen’s Salanersen Win Adds New Dimension To SMA Growth Story - Sahm
Biogen Inc (BIIB) Stock Price, Trades & News - GuruFocus
Biogen faces Italian antitrust probe over rivalry with Sandoz for MS drugs - MSN
Should Biogen’s (BIIB) New SMA Breakthrough and Lupus Data Prompt a Fresh Look From Investors? - Yahoo Finance
A Look At Biogen (BIIB) Valuation After New Breakthrough SMA Nod And Positive Lupus Phase 3 Data - Yahoo Finance
Biogen’s salanersen gets Breakthrough Therapy designation in SMA - The Pharma Letter
0.15%
0.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):